COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH USTEKINUMAB AS TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE IN THE UNITED STATES

被引：0
|
作者：
Zouraq, Azzabi, I [1 ]
Wilson, M. [2 ]
Hather, G. [3 ]
Curtis, R. [4 ]
Luo, M. [5 ]
Khalid, J. M. [4 ]
Minda, K. [1 ]
机构：
[1] Takeda Pharmaceut Int AG, Zurich, Switzerland
[2] RTI Hlth Sci, Res Triangle Pk, NC USA
[3] Takeda Pharmaceut, Cambridge, MA USA
[4] Takeda Dev Ctr Europe Ltd, London, England
[5] Takeda Pharmaceut Inc, Deerfield, IL USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI20
引用
收藏
页码：A183 / A183
页数：1
相关论文
共 50 条
  • [31] Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Gasink, Christopher
    Kowalski, Ken
    Sandborn, William J.
    Feagan, Brian
    CLINICAL THERAPEUTICS, 2022, 44 (10) : 1336 - 1355
  • [32] Safety of Ustekinumab With and Without Concomitant Corticosteroids or Immunosuppressants in Patients With Moderately-to-Severely Active Crohn's Disease
    Bruce, Sands
    Christopher, Gasink
    Douglas, Jacobstein
    Elyssa, Ott
    Lang Yinghua
    Paraneedharan, Ramachandran
    Subrata, Ghosh
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S24 - S24
  • [33] Vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a guide to its use
    Lyseng-Williamson K.A.
    Drugs & Therapy Perspectives, 2016, 32 (7) : 265 - 275
  • [34] Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
    Amanda Hansson-Hedblom
    Chrissy Almond
    Fredrik Borgström
    Indeg Sly
    Dana Enkusson
    Anders Troelsgaard Buchholt
    Linda Karlsson
    Cost Effectiveness and Resource Allocation, 16
  • [35] Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden
    Hansson-Hedblom, Amanda
    Almond, Chrissy
    Borgstrom, Fredrik
    Sly, Indeg
    Enkusson, Dana
    Buchholt, Anders Troelsgaard
    Karlsson, Linda
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2018, 16
  • [36] Cost-effectiveness of treatment with entacapone for patients with Parkinson's disease in the United States
    Palmer, C
    Nuijten, M
    Schmier, J
    Subedi, P
    Snyder, E
    ANNALS OF NEUROLOGY, 2000, 48 (03) : 496 - 496
  • [37] COST-EFFECTIVENESS OF ADALIMUMAB FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN CANADA
    Ghosh, S.
    Desjardins, O.
    Skup, M.
    Wang, S.
    Yang, M.
    Yang, H.
    Qi, C.
    Bao, Y.
    Chao, J.
    VALUE IN HEALTH, 2014, 17 (03) : A37 - A37
  • [38] COST-EFFECTIVENESS COMPARISON OF VEDOLIZUMAB, INFLIXIMAB AND CONVENTIONAL THERAPY FOR THE TREATMENT OF BIOLOGIC-NAIVE, MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS PATIENTS IN CHINA
    Sheng, Y.
    Ma, L.
    Chen, J.
    Xie, L.
    Zhao, W.
    Han, Y.
    VALUE IN HEALTH, 2020, 23 : S533 - S533
  • [39] COST UTILITY ANALYSIS OF VEDOLIZUMAB VERSUS CONVENTIONAL THERAPY FOR BIOLOGIC-NAIVE, MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PATIENTS IN CHINA
    Sheng, Y.
    Chen, J.
    Ma, L.
    Xie, L.
    Zhao, W.
    Han, Y.
    VALUE IN HEALTH, 2020, 23 : S533 - S533
  • [40] Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment
    Biemans, Vince B. C.
    van der Woude, C. Janneke
    Dijkstra, Gerard
    van der Meulen-de Jong, Andrea E.
    Lowenberg, Mark
    de Boer, Nanne K.
    Oldenburg, Bas
    Srivastava, Nidhi
    Jansen, Jeroen M.
    Bodelier, Alexander G. L.
    West, Rachel L.
    de Vries, Annemarie C.
    Haans, Jeoffrey J. L.
    de Jong, Dirk
    Hoentjen, Frank
    Pierik, Marieke J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (01) : 123 - 134
12345